GLPwatch
The impact of GLP-1 receptor agonist shortages on glycaemic Control: Findings from an Australian specialist diabetes clinic.
Diabetes Res Clin Pract · 2024
Last updated 2026-05-28Between January 2019 and October 2023, an Australian diabetes clinic tracked 811 adults with type 2 diabetes who had received at least two prescriptions for GLP-1 drugs. During a period of drug shortages, the average blood sugar control, measured by HbA1c, worsened by 0.3%.
AI summary of the abstract below.
| Journal | Diabetes Res Clin Pract, 2024 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.81 |
| NIH percentile | 43 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
There have been shortages of glucagon-like peptide-1 receptor agonists (GLP-1 RA) for type 2 diabetes (T2D) care. Analyses of data from 811 T2D adults at an Australian specialist diabetes clinic (1/2019-10/2023) who received ≥ 2 GLP-1 RA prescriptions before and during the shortage showed median HbA1c levels significantly increased by 0.3 %.
Verbatim abstract via PubMed 38852625 ↗